Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | AQP1 | P29972 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19300036 | 0.91 | KDM4E (0.59) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL2879559 | 0.91 | KDM4E (0.69) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL2879535 | 0.90 | LMNA (0.55) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL2875996 | 0.90 | ALDH1A1 (0.59) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL12522799 | 0.89 | KDM4E (0.58) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL14881379 | 0.87 | KDM4E (0.56) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL2881757 | 0.86 | ALDH1A1 (0.53) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL12522571 | 0.86 | ALDH1A1 (0.54) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL10169401 | 0.86 | KDM4E (0.51) | HPGDLMNAKDM4EALDH1A1USP2 | |
| SCHEMBL12522564 | 0.85 | ALDH1A1 (0.53) | HPGDLMNAKDM4EALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8008283-B2 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | AQP4, AVPR2, AQP1 | HPGD 241/4885LMNA 3676/4885KDM4E 3557/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | HPGD 1048/4885LMNA 4297/4885KDM4E 2764/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | HPGD 1760/4885LMNA 3023/4885KDM4E 3528/4885 |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SLC6A2, SLC1A2, SLC18A2 | HPGD 1879/4885LMNA 4437/4885KDM4E 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.